YS Biopharma Announces Name Change to LakeShore Biopharma
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced it is changing its legal name from "YS Biopharma Co., Ltd." to "LakeShore Biopharma Co., Ltd".
马里兰州盖瑟斯堡，2024 年 5 月 24 日 /PRNewswire/ — 致力于发现、开发、制造和交付用于传染病和癌症的新一代疫苗和治疗性生物制剂的全球生物制药公司YS Biopharma有限公司（Nasdaq: YS）（“YS Biopharma” 或 “公司”）今天宣布其法定名称从 “YS Biopharma Co..，有限公司” 改为 “湖岸生物制药有限公司”。
Dr. David Shao, Director, President, Co-Chief Executive Officer, and Chief Business Officer of the Company, commented, "We have decided to change our company name to LakeShore Biopharma to align with our global market positioning and international brand image. This change marks one of the first steps for us to expand our market reach, and we are eager to move forward and drive success under our new company name."
公司董事、总裁、联席首席执行官兼首席商务官邵大卫博士评论说：“我们决定将公司名称改为LakeShore Biopharma，以符合我们的全球市场定位和国际品牌形象。这一变化标志着我们扩大市场覆盖范围的第一步，我们渴望以新的公司名称向前迈进并推动成功。”
The name change and trading symbol change will not affect any rights of shareholders or the Company's operations and financial position. The Company's ordinary shares and warrants will continue to be listed on the Nasdaq. Effective with the opening of the trading day on May 28, 2024, the ticker symbol of the Company's ordinary shares and warrants will change from "YS" to "LSB" and from "YSBPW" to "LSBPW", respectively. There is no action required by the Company's current shareholders with respect to the company name or ticker symbol changes. The Company's CUSIP will not change in connection with the name change.
名称变更和交易代码变更不会影响股东的任何权利或公司的运营和财务状况。该公司的普通股和认股权证将继续在纳斯达克上市。自2024年5月28日交易日开盘起，公司普通股和认股权证的股票代码将分别从 “YS” 变为 “LSB”，从 “YSBPW” 更改为 “LSBPW”。公司现任股东无需就公司名称或股票代码的变更采取任何行动。公司的CUSIP不会因名称变更而发生变化。
About LakeShore Biopharma (formerly known as YS Biopharma)
关于 LakeShore Biopharma（前身为 YS Biopharma）
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
LakeShore Biopharma，前身为YS Biopharma，是一家全球生物制药公司，致力于发现、开发、制造和交付用于传染病和癌症的新一代疫苗和治疗性生物制剂。它开发了专有的PIKA免疫调节技术平台和针对狂犬病、冠状病毒、乙型肝炎、流感、带状疱疹和其他病毒感染的新一代预防和治疗生物制剂。该公司在中国、美国、新加坡和菲律宾开展业务，由管理团队领导，该团队结合了丰富的本地专业知识和生物制药行业的全球经验。欲了解更多信息，请访问investor.ysbiopharma.com。
Investor Relations Contact
投资者关系联系人
Alyssa Li
Director of Investor Relations
Email: [email protected]
Alyssa Li
投资者关系董事
电子邮件：[电子邮件保护]
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: [email protected]
杨罗宾
ICR, LLC 合伙人
电话：+1 (212) 537-4035
电子邮件：[电子邮件保护]
SOURCE YS Biopharma Co., Ltd.
来源 YS Biopharma Co., Ltd.